+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08075(KEL Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08075(KEL Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The Kell (KEL) blood group system, first identified in 1946. is a clinically significant antigen system encoded by the *KEL* gene located on chromosome 7q33. The KEL glycoprotein, a type II transmembrane metalloprotease, plays a role in cleaving endothelin-3 and other bioactive peptides. KEL antigens, including K (KEL1) and k (KEL2), are highly immunogenic, triggering antibody production upon exposure through transfusion, pregnancy, or transplantation. Anti-K antibodies are particularly notable in transfusion medicine and obstetrics due to their association with severe hemolytic reactions, including hemolytic disease of the fetus and newborn (HDFN).

Unlike the Rh system, KEL antigens are expressed early in erythropoiesis, making them targets for immune-mediated destruction of red blood cells. Anti-K is the most common immune antibody outside the ABO and Rh systems, with ~10% of incompatible transfusions leading to alloimmunization. In pregnancy, maternal anti-K can cause fetal anemia by suppressing erythropoiesis and lysing K-positive fetal cells. Detection of KEL antibodies relies on serological methods like indirect antiglobulin testing, while molecular genotyping aids in risk stratification. Prophylactic measures, including antigen-matched transfusions and antenatal monitoring, are critical in managing at-risk patients. Research continues to explore KEL's biological roles and strategies to mitigate antibody-mediated complications.